Related Experiment Video
Updated: Jan 3, 2026
Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method
Published on: April 18, 2019
[Chinese expert consensus on polymyxins in the clinical practice]
Chinese Research Hospital Association Of Critical Care Medicine, Chinese Research Hospital Association Of Evidence Base And Translational Infectious Diseases
Objective:
Polymyxin, a polypeptide antibiotic, derived from the culture of bacillus polymucilis, was introduced in the 1950s and used in clinical practice, but was replaced by safer antimicrobials due to its renal toxicity. In the recent years, with the increasing incidence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) bacilli infections, polymyxin is reintroduced into the clinic because it is assumed an important role in the treatment of MDR infections and XDR infections. In order to regulate the clinical applications of polymyxin, we organized experts in relevant fields to develop expert consensus on polymyxin for reference, including parameters like pharmacokinetics and pharmacodynamics, dosage and usage, contraindications and relative contraindications, clinical applications and adverse reactions.
Insights
Polymyxin antibiotics are back for multidrug-resistant infections, but experts created guidelines to ensure safe and effective clinical use, addressing toxicity concerns.
Area of Science:
- Infectious Diseases
- Pharmacology
- Microbiology
Background:
- Polymyxin, a polypeptide antibiotic, was clinically used but withdrawn due to renal toxicity.
- Resurgence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) bacterial infections necessitates polymyxin reintroduction.
- Need for standardized clinical application guidelines for polymyxin therapy.
Purpose of the Study:
- To develop an expert consensus on the clinical application of polymyxin.
- To provide guidance on pharmacokinetics, pharmacodynamics, dosage, and usage.
- To outline contraindications and adverse reactions for safe polymyxin use.
Main Methods:
- Convening a panel of experts in relevant medical fields.
- Reviewing existing literature on polymyxin.
- Developing consensus-based recommendations for clinical practice.
Main Results:
- Established parameters for polymyxin pharmacokinetics and pharmacodynamics.
- Defined appropriate dosage and usage guidelines.
- Identified contraindications, relative contraindications, and adverse reactions.
Conclusions:
- Expert consensus provides a framework for regulated clinical use of polymyxin.
- Addresses the critical need for managing MDR and XDR infections.
- Aims to optimize therapeutic outcomes while minimizing toxicity.
Related Concept Videos
01:27Combined Effects of Drugs: Synergism
Such synergistic combinations...
01:21Factors Affecting Dissolution: Polymorphism, Amorphism and Pseudopolymorphism
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
01:15Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations